Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intracoronary autologous bone marrow mononuclear cells in dilated cardiomyopathy
2013-002015-98Phase 3Terminated
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Jul 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in idiopathic dilated cardiomyopathy (IDC) and heart failure (HF) (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Clinical evaluation and determination of NYHA functional class. Started Jul 2013; status: terminated.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
idiopathic dilated cardiomyopathy (IDC)heart failure (HF)
Beyond the preview
Go deeper on 2013-002015-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002015-98.